Given aripiprazole’s prolactin-reducing properties and its clinical utility in managing antipsychotic-induced hyperprolactinemia, our study aims to investigate whether the risk of breast cancer differs in schizophrenia patients treated with aripiprazole compared to those treated with other antipsychotics. The gene discussed is PRL; the disease is hyperprolactinemia.